CHRS
Price
$1.49
Change
+$0.01 (+0.68%)
Updated
Jun 23, 04:02 PM (EDT)
Capitalization
228.29M
37 days until earnings call
Intraday BUY SELL Signals
NBTX
Price
$35.23
Change
-$1.04 (-2.87%)
Updated
Jun 22 closing price
Capitalization
1.76B
99 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CHRS vs NBTX

CHRS vs NBTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CHRS vs. NBTX commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Buy and NBTX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (CHRS: $1.48 vs. NBTX: $35.23)
Brand notoriety: CHRS and NBTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 81% vs. NBTX: 121%
Market capitalization -- CHRS: $228.29M vs. NBTX: $1.76B
CHRS [@Biotechnology] is valued at $228.29M. NBTX’s [@Biotechnology] market capitalization is $1.76B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 1 FA rating(s) are green whileNBTX’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 1 green, 4 red.
  • NBTX’s FA Score: 0 green, 5 red.
According to our system of comparison, CHRS is a better buy in the long-term than NBTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while NBTX’s TA Score has 1 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 2 bearish.
  • NBTX’s TA Score: 1 bullish, 7 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than NBTX.

Price Growth

CHRS (@Biotechnology) experienced а +8.82% price change this week, while NBTX (@Biotechnology) price change was -5.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.00%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was +1992.95%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 30, 2026.

NBTX is expected to report earnings on Sep 30, 2026.

Industries' Descriptions

@Biotechnology (+7.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBTX($1.76B) has a higher market cap than CHRS($228M). NBTX YTD gains are higher at: 52.379 vs. CHRS (4.225).
CHRSNBTXCHRS / NBTX
Capitalization228M1.76B13%
EBITDA-159.86MN/A-
Gain YTD4.22552.3798%
P/E Ratio3.24N/A-
Revenue46.9MN/A-
Total Cash167MN/A-
Total Debt40MN/A-
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
26
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
4
PRICE GROWTH RATING
1..100
46
P/E GROWTH RATING
1..100
73
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSNBTX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signal:
Gain/Loss:
NBTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NEHI25.950.48
+1.88%
NEOS Ethereum High Income ETF
CAFG32.570.09
+0.27%
Pacer US Small Cap Cash Cows Gr Ldrs ETF
LFAI148.42N/A
N/A
LifeX 2050 Longevity Income ETF
TBG36.50-0.07
-0.18%
TBG Dividend Focus ETF
EOS21.77-0.32
-1.45%
Eaton Vance Enhance Equity Income Fund II

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ARRY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
N/A
ARRY - CHRS
39%
Loosely correlated
+6.75%
AXON - CHRS
38%
Loosely correlated
-3.16%
NKTX - CHRS
37%
Loosely correlated
-2.27%
VIR - CHRS
36%
Loosely correlated
+4.48%
AMRN - CHRS
35%
Loosely correlated
-1.15%
More

NBTX and

Correlation & Price change

A.I.dvisor tells us that NBTX and CGEN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBTX and CGEN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBTX
1D Price
Change %
NBTX100%
-2.87%
CGEN - NBTX
33%
Poorly correlated
+3.23%
ALLO - NBTX
31%
Poorly correlated
+4.50%
NTLA - NBTX
31%
Poorly correlated
+0.51%
ASMB - NBTX
30%
Poorly correlated
+2.91%
CHRS - NBTX
29%
Poorly correlated
N/A
More